INTRODUCTION: Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive inherited disorder consisting of a triad of albinism, increased bleeding tendency secondary to platelet dysfunction, and systemic complications associated with ceroid depositions within the reticuloendothelial system. HPS has been associated with gastrointestinal (GI) complications related to chronic granulomatous colitis with pathologic features suggestive of Crohn's disease. This colitis can be severe and has been reported to be poorly responsive to medical therapies including antibiotics, corticosteroids, sulfasalazine, mesalamine and azathioprine. CASE PRESENTATION: We report a patient with HPS which was complicated by inflammatory bowel disease with clinical and pathologic features of Crohn's disease, refractory to antibiotics, corticosteroids and azathioprine. A trial of infliximab was attempted and repeated infusions produced a complete response. CONCLUSION: The occurrence of ileitis and perianal lesions and also the histopathological findings in our case suggest that HPS and Crohn's disease may truly be associated. Given this similarity and the failure of the standard medical therapy of corticosteroids and azathioprine, our patient received infliximab with marked clinical improvement.
INTRODUCTION:Hermansky-Pudlak syndrome (HPS) is a rare autosomal recessive inherited disorder consisting of a triad of albinism, increased bleeding tendency secondary to platelet dysfunction, and systemic complications associated with ceroid depositions within the reticuloendothelial system. HPS has been associated with gastrointestinal (GI) complications related to chronic granulomatous colitis with pathologic features suggestive of Crohn's disease. This colitis can be severe and has been reported to be poorly responsive to medical therapies including antibiotics, corticosteroids, sulfasalazine, mesalamine and azathioprine. CASE PRESENTATION: We report a patient with HPS which was complicated by inflammatory bowel disease with clinical and pathologic features of Crohn's disease, refractory to antibiotics, corticosteroids and azathioprine. A trial of infliximab was attempted and repeated infusions produced a complete response. CONCLUSION: The occurrence of ileitis and perianal lesions and also the histopathological findings in our case suggest that HPS and Crohn's disease may truly be associated. Given this similarity and the failure of the standard medical therapy of corticosteroids and azathioprine, our patient received infliximab with marked clinical improvement.
Authors: C J Witkop; M Nuñez Babcock; G H Rao; F Gaudier; C G Summers; F Shanahan; K R Harmon; D Townsend; H O Sedano; R A King Journal: Bol Asoc Med P R Date: 1990-08
Authors: Nadeem Hussain; Martha Quezado; Marjan Huizing; David Geho; James G White; William Gahl; Peter Mannon Journal: Clin Gastroenterol Hepatol Date: 2006-01 Impact factor: 11.382
Authors: Antoine de Leusse; Evelyne Dupuy; Marjan Huizing; Claire Danel; Guy Meyer; Raymond Jian; Philippe Marteau Journal: Gastroenterol Clin Biol Date: 2006-04
Authors: Alexis L Grucela; Pruthvi Patel; Eric Goldstein; Ron Palmon; David B Sachar; Randolph M Steinhagen Journal: Am J Gastroenterol Date: 2006-07-18 Impact factor: 10.864
Authors: Dhaarini Murugan; Michael H Albert; Jörg Langemeier; Jens Bohne; Jacek Puchalka; Päivi M Järvinen; Fabian Hauck; Anne K Klenk; Christine Prell; Stephanie Schatz; Jana Diestelhorst; Barbara Sciskala; Naschla Kohistani; Bernd H Belohradsky; Susanna Müller; Thomas Kirchner; Mark R Walter; Philip Bufler; Aleixo M Muise; Scott B Snapper; Sibylle Koletzko; Christoph Klein; Daniel Kotlarz Journal: J Clin Immunol Date: 2014-02-12 Impact factor: 8.317
Authors: Paul Girot; Catherine Le Berre; Astrid De Maissin; Marie Freyssinet; Caroline Trang-Poisson; Arnaud Bourreille Journal: World J Gastroenterol Date: 2019-02-28 Impact factor: 5.742
Authors: Marjan Huizing; May C V Malicdan; Jennifer A Wang; Hadass Pri-Chen; Richard A Hess; Roxanne Fischer; Kevin J O'Brien; Melissa A Merideth; William A Gahl; Bernadette R Gochuico Journal: Hum Mutat Date: 2020-01-23 Impact factor: 4.700